Researchers use machine learning to predict adverse events during stem cell therapy for multiple myeloma, improving outpatient safety.
Key Details
- 1Researchers analyzed data from 109 multiple myeloma patients undergoing stem cell mobilization.
- 2Machine learning models identified time periods with low risk for serious side effects during therapy.
- 3Models could accurately predict the timing and occurrence of certain side effects in individual patients.
- 4Enables more patients to safely undergo chemotherapy and stem cell mobilization as outpatients.
- 5Outpatient treatment improves quality of life and allows for better hospital resource management.
- 6Findings published in npj Digital Medicine by Göttingen and Bielefeld researchers.
Why It Matters
By accurately stratifying patient risk using AI, more multiple myeloma patients could receive therapy outside the hospital, reducing healthcare costs and improving patient experience. This study highlights the growing role for AI in personalizing oncology care pathways.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.